We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French biotech company Abivax has revealed positive topline results from a Phase IIb study of its investigational oral drug candidate ABX464 in ulcerative colitis (UC) patients.